Selina Becht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Selina Becht has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Tobias Weiglein
Department of Medicine III, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
3 shared publications- Ursula Marschall
BARMER, Wuppertal, Germany
3 shared publications - Alexander Philipp
Department of Medicine II, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
2 shared publications Bernhard Mörtl
Department of Medicine III, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
2 shared publications- Enrico N. De Toni
Department of Medicine II, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
2 shared publications Julia Mayerle
Department of Medicine II, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
2 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-11
Healthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment — A German Claims Data Study of 2778 Patients
- 2 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-11
Open AccessHealthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment — A German Claims Data Study of 2778 Patients
- Open Access
- 16 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15
What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study
Background: Geographic and temporal variations in the incidence and treatment of chronic viral hepatitis and trends in the development of metabolic and behavioral risk factors result in heterogeneous incidences of hepatocellular carcinoma (HCC). Therefore, national epidemiological information should be evaluated to identify the need for action. Methods: This retrospective observational study included adult patients with incident HCC (2016-2020). A network analysis was performed to investigate inter-relationships among risk factor diagnoses before HCC. Kaplan-Meier method and Cox proportional hazard model were used to analyze survival. Findings: A total of 2,778 patients were included. Mean age was 71.9 years (SD ±9.7); 69% were male. Most frequently documented risk factor diagnoses were diabetes mellitus (76%), obesity (56%), liver fibrosis/cirrhosis (44%), and alcohol abuse (36%). Hepatitis B and C were documented in 4% and 11% of patients. Behavioral and metabolic risk factors were 1.1-1.9-fold more frequent in men. Diabetes mellitus was the most central risk factor diagnosis co-occurring with other metabolic and behavioral risk factors. Median survival was 8.7 months. Interpretation: In this German cohort, risk factor diagnoses before HCC were multifactorial, with metabolic diseases most frequently co-occurring. Survival after HCC was poor. Controlling metabolic risk factors and surveilling at-risk populations are crucial to mitigating the incidence and improving the survival of HCC patients in Germany. Analyzing claims data enabled efficient and effective generation of epidemiological real-world evidence.
- 16 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15
Open AccessWhat can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study
Background: Geographic and temporal variations in the incidence and treatment of chronic viral hepatitis and trends in the development of metabolic and behavioral risk factors result in heterogeneous incidences of hepatocellular carcinoma (HCC). Therefore, national epidemiological information should be evaluated to identify the need for action. Methods: This retrospective observational study included adult patients with incident HCC (2016-2020). A network analysis was performed to investigate inter-relationships among risk factor diagnoses before HCC. Kaplan-Meier method and Cox proportional hazard model were used to analyze survival. Findings: A total of 2,778 patients were included. Mean age was 71.9 years (SD ±9.7); 69% were male. Most frequently documented risk factor diagnoses were diabetes mellitus (76%), obesity (56%), liver fibrosis/cirrhosis (44%), and alcohol abuse (36%). Hepatitis B and C were documented in 4% and 11% of patients. Behavioral and metabolic risk factors were 1.1-1.9-fold more frequent in men. Diabetes mellitus was the most central risk factor diagnosis co-occurring with other metabolic and behavioral risk factors. Median survival was 8.7 months. Interpretation: In this German cohort, risk factor diagnoses before HCC were multifactorial, with metabolic diseases most frequently co-occurring. Survival after HCC was poor. Controlling metabolic risk factors and surveilling at-risk populations are crucial to mitigating the incidence and improving the survival of HCC patients in Germany. Analyzing claims data enabled efficient and effective generation of epidemiological real-world evidence.
- Open Access
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths in Germany. National data on the management of HCC remain scarce. Objectives: This study aims to provide an up-to-date overview of clinical characteristics, treatment modalities, and survival outcomes among patients with HCC in Germany. Design: This is a real-world retrospective study using health insurance data from BARMER. Methods: Patients with an HCC diagnosis between 2016 and 2020 were identified in the BARMER database. Comorbidities, anticancer therapies, and treatment pathways of those patients were evaluated using descriptive statistics and survival analysis. Results: A total of 2778 patients with HCC were identified. Of these, 1569 (56.5%) received any anticancer therapy. Transarterial chemoembolization (TACE; 22.3%), liver resection (LR; 20.9%), and systemic therapy (18.9%) were the most frequently used approaches. Survival varied significantly, with liver transplantation (LTx) offering the best outcomes, with a 5-year survival rate of 76%, followed by LR with 40%. Treatments with curative intent, including LTx, LR, and ablation, had a median survival of 40.4 months, compared to 9.7 months for non-curative modalities. Conclusion: In Germany, a substantial proportion of HCC patients remain untreated. Therapies with curative intent, particularly transplantation, provide relevant survival benefits. Improving surveillance efforts could enhance the proportion of patients eligible for these modalities and may represent a critical step toward improved outcomes for patients with HCC.
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessTreatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths in Germany. National data on the management of HCC remain scarce. Objectives: This study aims to provide an up-to-date overview of clinical characteristics, treatment modalities, and survival outcomes among patients with HCC in Germany. Design: This is a real-world retrospective study using health insurance data from BARMER. Methods: Patients with an HCC diagnosis between 2016 and 2020 were identified in the BARMER database. Comorbidities, anticancer therapies, and treatment pathways of those patients were evaluated using descriptive statistics and survival analysis. Results: A total of 2778 patients with HCC were identified. Of these, 1569 (56.5%) received any anticancer therapy. Transarterial chemoembolization (TACE; 22.3%), liver resection (LR; 20.9%), and systemic therapy (18.9%) were the most frequently used approaches. Survival varied significantly, with liver transplantation (LTx) offering the best outcomes, with a 5-year survival rate of 76%, followed by LR with 40%. Treatments with curative intent, including LTx, LR, and ablation, had a median survival of 40.4 months, compared to 9.7 months for non-curative modalities. Conclusion: In Germany, a substantial proportion of HCC patients remain untreated. Therapies with curative intent, particularly transplantation, provide relevant survival benefits. Improving surveillance efforts could enhance the proportion of patients eligible for these modalities and may represent a critical step toward improved outcomes for patients with HCC.